Research Summary

Dr. Hala Borno is faculty at UCSF and an Assistant Professor in the Department of Medicine and Division of Hematology/Oncology. Dr. Borno is a medical oncologist with clinical expertise in the management of advanced urologic malignancies such as prostate, kidney, bladder, and testicular cancers. She cares for patients at the Helen Diller Family Comprehensive Cancer Center (HDFCCC) at the University of California San Francisco (UCSF). At HDFCCC, Dr. Borno serves on the executive leadership committee for the Prostate Cancer Program and the Liaison to the Office of Community Engagement. She is also a member of the American Society of Clinical Oncology Social Determinants of Health working group, GU committee for NRG oncology, and Health Disparities Committee for Alliance for Clinical Trials in Oncology.

Dr. Borno's research program consists of prostate cancer therapeutic development and cancer disparities. She serves as medical oncology co-chair for phase III clinical trials and is the principal investigator for clinical trials conducted at HDFCCC in advanced prostate cancer. Dr. Borno has an extensive research program on the promotion of equity in cancer precision medicine.

She has developed novel recruitment technologies that are clinician and patient facing to promote diversity and inclusion of racial/ethnic minorities in clinical trials. Dr. Borno used human-centered design to develop Trial LibraryTM, a patient facing clinical trial matching tool. Dr. Borno's research has been featured in peer-reviewed journals such JAMA Oncology, Cancer, and Nature. Her work has been covered by national news outlets such as NPR, Washington Post, CBS News, Bloomberg News, and STAT News.

Dr. Borno graduated with honors in biochemistry and received her medical degree from the University of North Carolina at Chapel Hill where she was a Medical Alumni Loyalty Fund Scholar. She completed her internal medicine residency and medical oncology fellowship training at UCSF. She served as chief oncology fellow at UCSF and was a National Institute on Aging T32 research fellow in the Division of Geriatrics.


University of North Carolina at Chapel Hill, B.S., 05/2008, Biochemistry
University of North Carolina at Chapel Hill, M.D., 05/2013, Medicine
University of California, San Francisco, Intern, 06/2014, Internal Medicine
University of California, San Francisco, Resident, 06/2016, Internal Medicine

Honors & Awards

  • 2009
    Foreign Language Area Studies Fellowship
  • 2011-2012
    Furlow Fund Global Health Research Fellowship, University of North Carolina at Chapel Hill
  • 2009-2013
    Medical Alumni Loyalty Fund Scholarship
  • 2013
    Arnold P. Gold Foundation
  • 2013
    Daniel T. Young Peace and Social Justice Award
  • 2017-present
    Geriatrics T32 NIH Grant
  • 2017-present
    Inside Out Accelerator Grant from the Clinical Innovation Center

Selected Publications

  1. Borno HT, Duffy C, Zhang S, Canchola AJ, Loya Z, Golden T, Oh DL, Odisho AY, Gomez S Integration of electronic pathology reporting with clinical trial matching for advanced prostate cancer.  View on PubMed
  2. Borno HT, Idossa D, Gomez SL Policy and Health: Leveraging a Social Determinants of Health Framework to Alleviate the Impact of the COVID-19 Pandemic on Patients With Cancer.  View on PubMed
  3. Borno HT, Kuo Lin T, Odisho AY, Desai A, Koshkin V, Werner K, Legaspi N, Bucknor M, Bell A, Zhang S, Hope TA Evaluating determinants of receipt of molecular imaging in biochemical recurrent prostate cancer.  View on PubMed
  4. Borno HT, Odisho AY, Gunn CM, Pankowska M, Rider JR Disparities in precision medicine-Examining germline genetic counseling and testing patterns among men with prostate cancer.  View on PubMed
  5. Hala Borno, Sylvia Zhang, Elena Nieves, Dana Dornsife, Robert G. Johnson, Darcy V. Spicer Utilization of a multisite financial reimbursement program to promote racial/ethnic diversity and inclusion in therapeutic cancer clinical trials: The iMPACT Study.  View on PubMed
  6. Bucknor MD, Lichtensztajn DY, Lin TK, Borno HT, Gomez SL, Hope TA Disparities in PET imaging for prostate cancer at a tertiary academic medical center.  View on PubMed
  7. Miaskowski C, Paul SM, Snowberg K, Abbott M, Borno H, Chang S, Chen LM, Cohen B, Hammer MJ, Kenfield SA, Kober KM, Levine JD, Pozzar R, Rhoads KF, Van Blarigan EL, Van Loon K Stress and Symptom Burden in Oncology Patients During the COVID-19 Pandemic.  View on PubMed
  8. Miaskowski C, Paul SM, Snowberg K, Abbott M, Borno H, Chang S, Chen LM, Cohen B, Cooper BA, Hammer MJ, Kenfield SA, Laffan A, Levine JD, Pozzar R, Tsai KK, Van Blarigan EL, Van Loon K Oncology patients' perceptions of and experiences with COVID-19.  View on PubMed
  9. Borno HT, Cowan JE, Zhao S, Broering JM, Carroll PR, Ryan CJ Examining initial treatment and survival among men with metastatic prostate cancer: An analysis from the CaPSURE registry.  View on PubMed
  10. Borno HT, Zhang S, Gomez S COVID-19 disparities: An urgent call for race reporting and representation in clinical research.  View on PubMed
  11. Borno HT, Lin TK, Batniji RS Determining the impact of Medicaid expansion on cancer burden.  View on PubMed
  12. Borno HT, Rider JR, Gunn CM The Ethics of Delivering Precision Medicine-Pretest Counseling and Somatic Genomic Testing.  View on PubMed
  13. DeRouen MC, McKinley M, Shah SA, Borno HT, Aoki R, Lichtensztajn DY, Leppert JT, Brooks JD, Chung BI, Gomez SL, Cheng I Testicular cancer in Hispanics: incidence of subtypes over time according to neighborhood sociodemographic factors in California.  View on PubMed
  14. Hala Borno, Kelvin A. Moses, Paul Monk, Kate Fitch, Matthew Harmon, Scott Flanders, Rana R. McKay Sipuleucel-T (sip-T) and oral androgen axis inhibitors in black men being treated for metastatic castration-resistance prostate cancer (mCRPC): Observations from the Medicare Fee for Service (FFS) population.  View on PubMed
  15. Barry Tong, Hala Borno, Eric Jay Small, Fern Alagala, Amie Blanco, Mallika Sachdev Dhawan Streamlining the genetics pipeline to increase testing for patients at risk for hereditary prostate cancer.  View on PubMed
  16. Borno HT, Zhang S, Bakke B, Bell A, Zuniga KB, Li P, Chao K, Sabol A, Killeen T, Hong H, Walter D, Loeb S Racial disparities and online health information: YouTube and prostate cancer clinical trials.  View on PubMed
  17. Borno HT, Small EJ Does the COVID-19 outbreak identify a broader need for an urgent transformation of cancer clinical trials research?  View on PubMed
  18. Cheung E, Borno HT The limitations of today's clinical guidance: Atypical femoral fracture and long-term bone-modifying agents in the oncology setting.  View on PubMed
  19. Hala Borno, Tracy Kuo Lin, Anobel Y. Odisho, Arpita Desai, Vadim S Koshkin, Kalin Werner, Nichole Legaspi, Alexander Bell, Thomas Hope Disparities in receipt of molecular imaging in biochemical recurrent prostate cancer.  View on PubMed
  20. Errol James Philip, Francis Wright, Daniel Myung Kim, Daniel Kwon, Hansen Ho, Son Ho, Edna Cheung, Emily Chan, Sima P. Porten, Anthony C. Wong, Hala Borno, Arpita Desai, Jonathan Chou, David Yoonsuk Oh, Rahul Raj Aggarwal, Lawrence Fong, Eric Jay Small, Terence W. Friedlander, Vadim S Koshkin Efficacy of immune checkpoint inhibitors (ICIs) in rare histological variants of bladder cancer.  View on PubMed

Go to UCSF Profiles, powered by CTSI